Drug repositioning

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the application of known drugs and compounds to treat a different disease.[1]

Smaller companies, including NovaLead Pharma,Ore Pharmaceuticals, Biovista, Numedicus, Melior Discovery and SOM Biotech are also performing drug repositioning on a systematic basis.[1][2] These companies use a combination of approaches including in silico biology and in vivo/in vitro experimentation to assess a compound and develop and confirm hypotheses concerning its usage for new indications.

Using drug repositioning, pharmaceutical companies have achieved a number of successes; for example, Pfizer's Viagra for erectile dysfunction and Celgene's thalidomide for cancer.[3][4]

See also[edit]

References[edit]

  1. ^ a b Sleigh SH, Barton CL (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811. 
  2. ^ "Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review". Drug Discovery World. Retrieved 1 May 2015. 
  3. ^ Ashburn TT, Thor KB (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–83. doi:10.1038/nrd1468. PMID 15286734. 
  4. ^ Institute of Medicine (2014). Drug Repurposing and Repositioning: Workshop Summary. National Academies Press. ISBN 978-0-309-30204-3. 

Further reading[edit]